A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

The results from this study demonstrated that gefitinib inhibited the phosphorylation of EGFR in EOC tumor cells, providing proof of target in a clinical setting. Combinatorial therapy with molecular therapeutics against complementary targets may prove successful.